Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tarsus Pharmaceuticals, Inc.

43.25
+1.854.47%
Post-market: 43.250.00000.00%16:04 EDT
Volume:1.26M
Turnover:55.02M
Market Cap:1.82B
PE:-15.91
High:45.48
Open:43.26
Low:42.43
Close:41.40
Loading ...

Tarsus to Participate in Upcoming Investor Conference

GlobeNewswire
·
07 Mar

Tarsus Pharmaceuticals price target raised to $58 from $54 at Jefferies

TIPRANKS
·
07 Mar

Barclays Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
06 Mar

Tarsus Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
27 Feb

Stock Track | Tarsus Pharmaceuticals Soars 5.74% as Strong 2024 Results Fuel Growth Momentum

Stock Track
·
26 Feb

Tarsus Pharmaceuticals Price Target Maintained With a $73.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Feb

Tarsus Pharmaceuticals: Strong Earnings and Growth Potential Make It a Buy

TIPRANKS
·
26 Feb

Tarsus Pharmaceuticals: Undervalued Growth Potential and Acquisition Appeal Reinforce Buy Rating

TIPRANKS
·
26 Feb

Tarsus Pharmaceuticals price target lowered to $60 from $62 at Barclays

TIPRANKS
·
26 Feb

Tarsus Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
26 Feb

Q4 2024 Tarsus Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
26 Feb

Tarsus Pharmaceuticals Inc (TARS) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ...

GuruFocus.com
·
26 Feb

Tarsus Pharmaceuticals Reports Strong 2024 Financial Results

TIPRANKS
·
26 Feb

Stock Track | Tarsus Pharmaceuticals Plummets 11.19% After Q4 Earnings and Price Target Cut

Stock Track
·
26 Feb

Tarsus Pharmaceuticals price target lowered to $70 from $75 at BofA

TIPRANKS
·
26 Feb

Tarsus Pharmaceuticals: Strong Buy Rating Driven by Impressive Financial Performance and Strategic Growth Positioning

TIPRANKS
·
26 Feb

Tarsus Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
25 Feb

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday

MT Newswires Live
·
25 Feb

Tarsus Pharmaceuticals Q4 Loss Narrows, Revenue Rises

MT Newswires Live
·
25 Feb

Earnings Flash (TARS) Tarsus Pharmaceuticals Posts Q4 Net Loss $-0.60 a Share, vs. FactSet Est of $-0.87 Loss

MT Newswires Live
·
25 Feb